



Short Communication

Methylenetetrahydrofolate reductase deficiency alters levels of glutamate and γ -aminobutyric acid in brain tissueN.M. Jadavji^{a,*}, F. Wieske^b, U. Dirnagl^{a,c}, C. Winter^b^a Department of Experimental Neurology, Center for Stroke Research Berlin, Charité University Medicine Berlin, Germany^b Department of Experimental Psychiatry, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany^c German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany

ARTICLE INFO

Article history:

Received 12 December 2014

Received in revised form 6 February 2015

Accepted 6 February 2015

Available online 20 February 2015

Keywords:

Methylenetetrahydrofolate reductase

S-Adenosylmethionine

Homocysteine

Monoamine neurotransmitters

Glutamate

 γ -Aminobutyric acid

ABSTRACT

Methylenetetrahydrofolate reductase (MTHFR) is an enzyme key regulator in folate metabolism. Deficiencies in MTHFR result in increased levels of homocysteine, which leads to reduced levels of S-adenosylmethionine (SAM). In the brain, SAM donates methyl groups to catechol-O-methyltransferase (COMT), which is involved in neurotransmitter analysis. Using the MTHFR-deficient mouse model the purpose of this study was to investigate levels of monoamine neurotransmitters and amino acid levels in brain tissue. MTHFR deficiency affected levels of both glutamate and γ -aminobutyric acid in within the cerebellum and hippocampus. *Mthfr*^{-/-} mice had reduced levels of glutamate in the amygdala and γ -aminobutyric acid in the thalamus. The excitatory mechanisms of homocysteine through activation of the N-methyl-D-aspartate receptor in brain tissue might alter levels of glutamate and γ -aminobutyric acid.

© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme in folate metabolism since it generates the main circulating form of folate, 5-methyltetrahydrofolate (5-methylTHF), which can serve as a methyl donor for the remethylation of homocysteine to methionine and subsequently the generation of S-adenosylmethionine (SAM) (Fig. 1). Through methylation SAM is involved in lipid metabolism and also donates a methyl group to catechol-O-methyltransferase (COMT), which catalyzes synthesis of neurotransmitters in the brain [1,2]. Increased levels of homocysteine, as a result of folate deficiency, have been linked to low levels of monoamine neurotransmitter levels in patients with depression [3].

Many polymorphisms of MTHFR have been described in the human population and the most common is a polymorphism at base pair 677, a conversion from C to T which results in a missense mutation causing an

alanine to valine conversion [4]. Homozygosity has been reported in 5–20% of North American and European populations [5]. These individuals have reduced enzyme activity (heterozygotes 65% and homozygotes 30% compared to controls [6]) and slightly elevated levels of plasma homocysteine, which is highly dependent on folate status [5,7]. Individuals with the TT genotype have increased risk of developing cognitive impairment [8], late onset Alzheimer's disease [9], as well as depression and schizophrenia [10]. Another condition involved in MTHFR deficiency is an inborn error of metabolism, which results in a severe deficiency in the enzyme and leads to homocystinuria. Patients with a severe MTHFR deficiency have significantly elevated levels of homocysteine and reduced levels of methionine and present with neurological and vascular complications [11–13].

In order to investigate the effects of MTHFR deficiency on neurological function in vivo, a knockout mouse model for MTHFR was developed, *Mthfr*^{+/-} and *Mthfr*^{-/-} mice have elevated levels of plasma homocysteine [14]. *Mthfr*^{+/-} mice model the polymorphism at base pair 677, as they have elevated levels of plasma homocysteine when compared to wildtype mice but are phenotypically normal. Whereas *Mthfr*^{-/-} mice model the severe form of MTHFR deficiency, these mice have significantly elevated levels of homocysteine and have motor and cognitive impairments [15]. In brain tissue, both *Mthfr*^{+/-} and *Mthfr*^{-/-} mice have significantly reduced levels of DNA methylation and S-adenosylhomocysteine [14] and *Mthfr*^{-/-} mice have reduced levels of 5-methylTHF [14,16] and SAM [14]. Additionally, behavioral studies have reported impairments in cognitive and motor function

Abbreviations: 5-HIAA, 5-hydroxyindoleacetic acid; 5-methylTHF, 5-methyltetrahydrofolate; COMT, catechol-O-methyltransferase; HPLC, high performance liquid chromatography; MTHFR, methylenetetrahydrofolate reductase; SAM, S-adenosylmethionine; GABA, γ -aminobutyric acid; DOPAC, 3,4-dihydroxyphenylacetic acid; HVA, homovanillic acid; 5-HT, serotonin.

* Corresponding author at: Department for Experimental Neurology, Charité University Medicine Berlin, 10117 Berlin Germany.

E-mail addresses: nafisa.jadavji@charite.de (N.M. Jadavji), Franziska.Wieske@uniklinikum-dresden.de (F. Wieske), ulrich.dirnagl@charite.de (U. Dirnagl), Christine.Winter@uniklinikum-dresden.de (C. Winter).

[15,17]. The purpose of this study was to investigate whether levels of monoamine neurotransmitters and amino acids are altered in different brain regions of MTHFR-deficient mice.

2. Materials and methods

All experiments were approved by the Landesamt für Gesundheit und Soziales Berlin and performed in accordance with the German Animal Welfare Act. At 3-months of age blood and brain tissue from C57BL/6 male mice was collected and processed for post-mortem neurochemical analyses using high performance liquid chromatography (HPLC) as described previously [18]. The levels of dopamine, serotonin, and their metabolites dihydroxyphenylacetic acid (DOPAC) and 5-hydroxyindoleacetic acid (5-HIAA) in the amygdala, caudate putamen, cerebellum, dorsal raphe, hippocampus, medial prefrontal cortex, nucleus accumbens, and thalamus, amygdalae were measured by HPLC with electrochemical detection. Glutamate and γ -aminobutyric acid (GABA) were determined by HPLC with fluorescence detection. We worked with male mice in this study to avoid sex differences that have been previously described in MTHFR mice [19] and neurotransmitter analysis [20].

Blood samples taken from the same mice were centrifuged at $7000 \times g$ for 7 min at 4°C to obtain the plasma. HPLC was used to measure plasma homocysteine concentrations by a diagnostic laboratory at Charite University Medicine (Labor 28, Berlin).

One-way analysis of variance (ANOVA) was used to compare genotype groups for each measurement followed by Tukey's post-hoc test if applicable. Significance level was set at $p \leq 0.05$.

3. Results

Mthfr^{+/-} and *Mthfr*^{-/-} had significantly higher plasma homocysteine levels when compared to *Mthfr*^{+/+} mice (Table 1, $p < 0.05$).

There were few changes in monoamine neurotransmitter levels and respective metabolites. Serotonin levels were increased in *Mthfr*^{-/-} in the amygdala when compared to *Mthfr*^{+/+} mice (Table 1, $p < 0.05$). Dopamine levels within the cerebellum were different between genotype groups (Table 1, one-way ANOVA, $F(2, 23) = 8.45$, $p < 0.01$). 5-HIAA was increased in the cerebellum of *Mthfr*^{+/-} (Table 1, $p < 0.05$) and there was a genotype effect in the hippocampus (Table 1, one-way ANOVA, $F(2, 21) = 3.35$, $p < 0.05$).

Glutamate levels were different between genotype groups within the amygdala (Table 1, one-way ANOVA, $F(2, 21) = 3.45$, $p < 0.05$). *Mthfr*^{-/-} mice had reduced levels of glutamate in the cerebellum (Table 1, $p < 0.05$) compared to *Mthfr*^{+/-} mice, and hippocampus (Table 1, $p < 0.05$) compared to *Mthfr*^{+/+} mice. Cerebellar GABA levels were increased in *Mthfr*^{+/-} and *Mthfr*^{-/-} when compared to *Mthfr*^{+/+} mice (Table 1, $p < 0.05$). While, GABA levels were reduced in hippocampus (Table 1, $p < 0.05$) and thalamus (Table 1, $p < 0.05$) of *Mthfr*^{-/-} mice compared to *Mthfr*^{+/+}.

4. Discussion

Increased levels of plasma homocysteine have been linked to impaired monoamine synthesis as a result of reduced levels of SAM [1]. In the present study using a hyperhomocysteinemic MTHFR-deficient mouse model we investigated levels of the monoamine neurotransmitters, dopamine, 5-HT, and their respective metabolites, as well as the amino acids, glutamate and GABA in different brain areas. We confirmed that *Mthfr*^{+/-} (~14 μM) and *Mthfr*^{-/-} (~70 μM) have significantly elevated levels of plasma homocysteine as previously reported in earlier work [14,15,21]. We identified that *Mthfr*^{-/-} have increased levels of serotonin in the amygdala, whereas *Mthfr*^{+/-} have increased levels of cerebellar dopamine levels. Levels of 5-HIAA are increased in *Mthfr*^{+/-} mice in the cerebellum and reduced in the hippocampus of *Mthfr*^{+/-} and *Mthfr*^{-/-} mice. Additionally, hippocampal levels of HVA




Fig. 1. One-carbon metabolism and related biological roles (methylation and nucleotide synthesis). Enzymes indicated in black circles. Abbreviations: BHMT – betaine homocysteine methyltransferase; CHDH – choline dehydrogenase; COMT – catechol-O-methyltransferase; DHFR – dihydrofolate reductase; dTMP – deoxythymidine monophosphate; dTTP – deoxythymidine triphosphate; dUMP – deoxyuridine monophosphate; dUTP – deoxyuridine triphosphate; FR – folate receptor; MTHFR – methylenetetrahydrofolate reductase; MTR – methionine synthase; MTRR – methionine synthase reductase; RFC – reduced folate carrier; SAM – S-adenosylmethionine; SAH – S-adenosylhomocysteine; and TS – thymidylate synthase.

Download English Version:

<https://daneshyari.com/en/article/2058809>

Download Persian Version:

<https://daneshyari.com/article/2058809>

[Daneshyari.com](https://daneshyari.com)